Engaging CD4 T cells in anti-tumor immunity has been quite challenging, especially in an antigen specific manner, since most human solid tumors usually do not express MHC class II molecules. We have recently shown that human CD4 T cells engineered to express a human melanoma associated antigenic epitope, MART-127-35, specific MHC class I restricted transgenic T cell receptor (TCR) function as polyfunctional effectors that can exhibit a helper as well as cytolytic effector function, in an epitope specific and MHC class I restricted manner (Chhabra et al., JI, 2008, Ray et al., J. Clin. Immunol., 2010). TCR engineered (TCReng) CD4 T cells therefore have translational potential and clinical trials with MHC class I TCR engineered CD4 T cells are underway. We here show that while TCReng CD4 T cells could be useful in cancer immunotherapy, they are also susceptible to epitope specific AICD. We also show that the AICD in TCReng CD4 T cells is a death receptor (DR)-independent process, and that JNK andp53 play critical roles in this process as pharmacological inhibitors targeting JNK activation and p-53 mediated transcription-independent mitochondria-centric death cascade rescued a significant fraction of TCReng CD4 T cells from undergoing AICD without affecting their effector function. Our data offer novel insights towards AICD in TCReng CD4 T cells and identify several potential targets to interfere with this process.